Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Global Approaches to the Frontline Management of CLL

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

Recommendations for CAR T-Cell Therapy in R/R DLBCL

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

Case 1: 75-Year-Old Man With SM

August 9th 2021

Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.

Newer Approvals for Previously Treated DLBCL

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

Considerations in SM: Hereditary Alpha Tryptasemia

August 9th 2021

Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.

FDA Places Partial Clinical Hold on Trials Examining Eprenetapopt/Azacitidine for Myeloid Malignancies

August 6th 2021

The FDA has placed a partial clinical hold on clinical trials examining the combination of eprenetapopt and azacitidine in patients with myeloid malignancies.

Treatment of Transfusion Dependent MDS

August 6th 2021

The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.

Luspatercept: An Erythroid Maturation Agent in MDS

August 6th 2021

Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.

Clinical Considerations in the Diagnosis of MDS

August 5th 2021

Drs Madanat and Sekeres comment on the various risk stratification factors and prognostic criteria used in the classification of MDS disease.

The Role of IDH Inhibitors for Treatment of AML

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).

Combining and Sequencing FLT3 Inhibitors in AML

August 5th 2021

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Classification of Myelodysplastic Syndrome

August 5th 2021

Yazan Madanat, M.D and Mikkael A. Sekeres, M.D. discuss considerations in the classification of myelodysplastic syndrome taking into account disease heterogeneity.

Low-Dose Venetoclax Achieves Promising Results in AL Amyloidosis and Myeloma Subsets

August 5th 2021

Low-dose venetoclax monotherapy demonstrated antitumor activity in patients with heavily pretreated multiple myeloma and light chain amyloidosis harboring t(11;14).

BMS Withdraws Romidepsin Relapsed/Refractory PTCL Indication in the United States

August 3rd 2021

Bristol Myers Squibb has made the decision to withdraw in the indication for romidepsin as a monotherapy for the treatment of adult patients with peripheral T-cell lymphoma who have previously received at least 1 therapy.

Approaches to Treatment of Ph- ALL

August 3rd 2021

Ibrahim Aldoss, MD; and James K. McCloskey, MD, discuss how to approach the treatment of a pediatric or AYA patient with ALL who is Philadelphia chromosome-negative (Ph-).

Treating Ph+ ALL: The GIMEMA Trial

August 3rd 2021

A review of the design, results, and practical implications of the GIMEMA Trial.

Considerations in Mast Cell Disorders

August 2nd 2021

The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.

Systemic Mastocytosis: Epidemiology and Diagnostic Criteria

August 2nd 2021

Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML

August 2nd 2021

The combination of ivosidenib plus azacitidine significantly improved event-free survival compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE trial.

DLBCL: Approaches to Treating Patients Ineligible for Transplant

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.